XML 114 R54.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Details 3) (USD $)
3 Months Ended 3 Months Ended
Jun. 30, 2013
Dec. 31, 2012
Mar. 31, 2013
Suncare and skincare brands
Jun. 30, 2013
Suncare and skincare brands
Mar. 31, 2013
Dermatology products
Jun. 30, 2013
Fair Value, Measurements, Nonrecurring
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis            
Impairment charges on intangible assets     $ 26,100,000   $ 5,700,000  
Adjusted carrying value of intangible assets 8,723,168,000 [1] 8,761,793,000 [1]   44,400,000 1,000,000  
Total financial liability           $ 0
[1] In the first quarter of 2013, the Company recognized a write-off of $22.2 million related to Opana®, a pain relief medication approved in Canada, due to production issues arising in the first quarter of 2013. These production issues resulted in higher spending projections and delayed commercialization timelines which, in turn, triggered the Company’s decision to suspend its launch plans. The Company does not believe this program has value to a market participant. This write-off was recognized in Amortization of intangible assets in the consolidated statements of income (loss). For further information regarding asset impairment charges, see note 7 titled “FAIR VALUE MEASUREMENTS”.